Psoriasis News and Research

Latest Psoriasis News and Research

Phenex Pharmaceuticals announces closure of Series C financing round

Phenex Pharmaceuticals AG, a drug discovery and development company headquartered in Ludwigshafen, Germany, today announced the closure of its Series C financing round with a volume of 6 M € (7,8 M USD) bringing the total amount of funds raised to 17,2 M € (22,4 M USD).

21 Sep 2010

Arrayit installs microarray platform at NIH

Arrayit Corporation has completed installation and technical training of its proprietary microarray platform at the National Institute of Mental Health, National Institutes of Health, in Rockville, Maryland. In 2010, the NIH will invest more than $31.2 billion in medical research for the American people through 50,000 competitive grants to 325,000 researchers at 3,000 universities, hospitals, companies, medical schools and scientific institutions in the United States and around the world.

21 Sep 2010

Provectus completes enrollment in first cohort of PV-10 Phase 1 trial for liver cancer

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that it has completed enrollment in the first of two dose cohorts in its Phase 1 clinical trial of PV-10 for liver cancer, and that the therapy was very well tolerated by all three subjects treated, with substantial evidence of efficacy.

15 Sep 2010

VBL Therapeutics' VB-201 candidate delays onset of EAE, shows potential for MS, CNS treatment

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the publication of preclinical data in the Journal of Neuroimmunology finding that its lead development candidate VB-201 significantly delayed the onset and severity of experimental autoimmune encephalomyelitis (EAE) in mice, the commonly used Multiple sclerosis.

14 Sep 2010

Provectus's PV-10 Phase 2 data to be presented at 7th International Melanoma Research Congress

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 PV-10 metastatic melanoma study will be presented at the 7th International Melanoma Research Congress in Sydney, Australia, on November 4, 2010 at 4:30 p.m., as part of the 4th Interdisciplinary Melanoma & Skin Cancer Centres Meeting,

13 Sep 2010

Santarus expands development pipeline, adds two novel biologic drug candidates

Santarus, Inc., a specialty biopharmaceutical company, has expanded its development pipeline with the addition of two novel biologic drug candidates focused on specialty markets.

13 Sep 2010

Anacor Pharmaceuticals files registration statement with U.S. SEC for initial public offering

Anacor Pharmaceuticals, Inc. today announced that it has filed a registration statement with the U.S. Securities and Exchange Commission ("SEC") relating to the proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. All shares of the common stock to be sold in the offering will be offered by Anacor.

13 Sep 2010

Diplomat Specialty Pharmacy ranked #554 on Inc.'s Top 5000 list of fastest-growing private companies

Diplomat Specialty Pharmacy announced today they have earned a position of 554 on Inc. Magazine's exclusive, annual ranking of the fastest-growing private companies in America.

10 Sep 2010

GE Global Researchers receive award from NIH for human microbiome study

Researchers from GE Global Research have been awarded a $538,000 human microbiome project from the National Institutes of Health (NIH) to develop new technology that would allow for the study of individual cells growing inside and outside the body believed to have a significant impact on human health.

8 Sep 2010

Researchers receive BioBank DNA samples to unveil psoriasis genetics

Millions of Americans struggling with psoriasis and psoriatic arthritis are one step closer to a cure with the release of the first National Psoriasis Victor Henschel BioBank DNA samples for use in research at the University of Michigan Health System; research that hopes to uncover the unknowns about the genetics of psoriasis and psoriatic arthritis.

3 Sep 2010

Intendis granted rights to KYTHERA's ATX-101 candidate for minimally-invasive fat reduction outside US, Canada

KYTHERA Biopharmaceuticals, Inc. and Intendis, Bayer HealthCare's dermatology business, today announced that they have entered into a licensing agreement granting Intendis rights to KYTHERA's lead product candidate, ATX-101, outside of the US and Canada. ATX-101, a first-in-class investigational drug, is currently in clinical development for the reduction of localized fat under the chin (submental fat).

31 Aug 2010

FDA approves Chelsea Therapeutics' Phase II protocol for CH-4051 antifolate in rheumatoid arthritis

Chelsea Therapeutics International, Ltd. announced confirmation by the U.S. Food and Drug Administration (FDA) that its proposed Phase II protocol for CH-4051 in rheumatoid arthritis has been approved by the agency.

26 Aug 2010

3Sbio, Isotechnika Pharma sign development and commercialization agreement for voclosporin inhibitor

Isotechnika Pharma Inc., a biopharmaceutical company focused on the discovery and development of immune modulating therapeutics, and 3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced the signing of a development and commercialization agreement for voclosporin, a next generation calcineurin inhibitor being developed for use in the prevention of organ rejection following transplantation and the treatment of autoimmune diseases.

25 Aug 2010

3SBio and Isotechnika enter strategic agreement for voclosporin in China

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products and Isotechnika Pharma Inc., a biopharmaceutical company focused on the discovery and development of immune modulating therapeutics, today announced the signing of a development and commercialization agreement for voclosporin.

24 Aug 2010

Beer psoriasis link for women and psoriasis plus depression

According to a new study, women who regularly drink beer may be increasing their risk of developing psoriasis – a disease of the skin. Light beer and wine are not associated with such a risk, the study says. Psoriasis is a chronic skin disease characterised by itchy red scaly patches that most commonly appear on the knees, elbows and scalp or anywhere else in the body.

23 Aug 2010

Lotus Pharmaceuticals second-quarter net income increases 32% to $6.3 million

Lotus Pharmaceuticals, Inc., a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China, reported today its financial results for the quarter and six months ended June 30, 2010.

16 Aug 2010

Avenue to Access provides free prescription-size tube of ZITHRANOL-RR to stable plaque psoriasis patients

During the month of August, people with a certain type of psoriasis have the chance to access free medicine through Avenue to Access. The program is designed to help individuals with mild-to-moderate stable plaque psoriasis access to a free prescription-size tube of ZITHRANOL-RR (anthralin, 1.2%) rapid release microcrystalline encapsulated cream.

16 Aug 2010

CADTH Review Panel releases recommendations for Biologic Response Modifier Agents for Adults with RA

The Canadian Agency for Drugs and Technologies in Health's (CADTH) Therapeutic Review Panel released last week their recommendations for Biologic Response Modifier Agents for Adults with Rheumatoid Arthritis (RA).

10 Aug 2010

Analysis finds no evidence that inclusion of retinyl palmitate in sunscreens can cause cancer

Despite previous concerns about the cancer-causing potential of sunscreens containing retinyl palmitate (vitamin A), an independent analysis published online in the Journal of the American Academy of Dermatology determined that there is no evidence that the inclusion of retinyl palmitate in sunscreens can cause cancer in humans.

10 Aug 2010

Three-year efficacy data on STELARA for psoriasis presented at American Academy of Dermatology meeting

New study findings showed that a majority of patients with moderate to severe plaque psoriasis who had a previous response to STELARA® (ustekinumab) sustained a clinical response for up to three years with continued treatment regardless of their body weight. Investigators also presented findings from an integrated safety analysis that included data from one Phase 2 and three Phase 3 trials in which treatment with STELARA demonstrated a favorable benefit-risk profile for up to three years of treatment, consistent with previous analyses.

10 Aug 2010

Psoriasis News and Research

Latest Psoriasis News and Research

Phenex Pharmaceuticals announces closure of Series C financing round

Arrayit installs microarray platform at NIH

Provectus completes enrollment in first cohort of PV-10 Phase 1 trial for liver cancer

VBL Therapeutics' VB-201 candidate delays onset of EAE, shows potential for MS, CNS treatment

Provectus's PV-10 Phase 2 data to be presented at 7th International Melanoma Research Congress

Santarus expands development pipeline, adds two novel biologic drug candidates

Anacor Pharmaceuticals files registration statement with U.S. SEC for initial public offering

Diplomat Specialty Pharmacy ranked #554 on Inc.'s Top 5000 list of fastest-growing private companies

GE Global Researchers receive award from NIH for human microbiome study

Researchers receive BioBank DNA samples to unveil psoriasis genetics

Intendis granted rights to KYTHERA's ATX-101 candidate for minimally-invasive fat reduction outside US, Canada

FDA approves Chelsea Therapeutics' Phase II protocol for CH-4051 antifolate in rheumatoid arthritis

3Sbio, Isotechnika Pharma sign development and commercialization agreement for voclosporin inhibitor

3SBio and Isotechnika enter strategic agreement for voclosporin in China

Beer psoriasis link for women and psoriasis plus depression

Lotus Pharmaceuticals second-quarter net income increases 32% to $6.3 million

Avenue to Access provides free prescription-size tube of ZITHRANOL-RR to stable plaque psoriasis patients

CADTH Review Panel releases recommendations for Biologic Response Modifier Agents for Adults with RA

Analysis finds no evidence that inclusion of retinyl palmitate in sunscreens can cause cancer

Three-year efficacy data on STELARA for psoriasis presented at American Academy of Dermatology meeting

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Psoriasis News and Research

Latest Psoriasis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in